日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Targeting NOTCH3 to eradicate dormant and therapy-resistant multiple myeloma cells.

靶向 NOTCH3 以根除休眠和耐药的多发性骨髓瘤细胞。

Sabol Hayley M, Paxton Bethany C, Anloague Aric, Kaur Japneet, Nester Mattie R, Khan Sharmin, Smith James, Croucher Peter I, McDonald Michelle M, Montgomery Corey O, Stambough Jeffrey B, Barnes C Lowry, Ambrogini Elena, Ebetino Frank H, Schinke Carolina, Ashby Cody, Delgado-Calle Jesús

Correction: Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study

更正:Onvansertib联合FOLFIRI和贝伐单抗二线治疗KRAS突变转移性结直肠癌:一项Ib期临床研究

Ahn, Daniel H; Barzi, Afsaneh; Ridinger, Maya; Samuëlsz, Errin; Subramanian, Ramanand A; Croucher, Peter J P; Smeal, Tod; Kabbinavar, Fairooz F; Lenz, Heinz-Josef

Uncoupled bone remodeling drives myeloma bone disease in Vk*MYC mouse model of multiple myeloma

在多发性骨髓瘤Vk*MYC小鼠模型中,骨重塑脱钩驱动骨髓瘤骨病。

Schmal, Clarissa; Simic, Marija K; Xiao, Ya; Catala, Alicia A; Jiang, Millie; Andersen, Thomas Levin; Diaz-delCastillo, Marta; Croucher, Peter; McDonald, Michelle; Jafari, Abbas

Etiquette in the Context of Death and Dying: Communication and Conversation

临终关怀中的礼仪:沟通与对话

Dayes, Jennifer; Keenan, Joseph; Sadza, Michal; Croucher, Karina

Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial

Onvansertib 联合化疗和贝伐单抗用于 KRAS 突变转移性结直肠癌的二线治疗:一项单组 II 期试验

Daniel H Ahn, Maya Ridinger, Timothy L Cannon, Lawrence Mendelsohn, Jason S Starr, Joleen M Hubbard, Anup Kasi, Afsaneh Barzi, Errin Samuëlsz, Anju Karki, Ramanand A Subramanian, Divora Yemane, Roy Kim, Chu-Chiao Wu, Peter J P Croucher, Tod Smeal, Fairooz F Kabbinavar, Heinz-Josef Lenz

Genetic population structure of Haemophilus influenzae at local and global scales

局部和全球尺度上流感嗜血杆菌的遗传群体结构

MacAlasdair, Neil; Pöntinen, Anna K; Ling, Clare; Mallawaarachchi, Sudaraka; Thaipadungpanit, Janjira; Nosten, Francois H; Turner, Claudia; Bentley, Stephen D; Croucher, Nicholas J; Turner, Paul; Corander, Jukka

Activation of CAMK2 by pseudokinase PEAK1 represents a targetable pathway in triple negative breast cancer

假激酶 PEAK1 激活 CAMK2 是三阴性乳腺癌中可靶向的通路

Xue Yang, Xiuquan Ma, Tianyue Zhao, David R Croucher, Elizabeth V Nguyen, Kimberley C Clark, Changyuan Hu, Sharissa L Latham, Charles Bayly-Jones, Bao V Nguyen, Srikanth Budnar, Sung-Young Shin, Lan K Nguyen, Thomas R Cotton, Anderly C Chüeh, Terry C C Lim Kam Sian, Margaret M Stratton, Andrew M Ell

Age-related mesenchymal stromal cell senescence is associated with progression from MGUS to multiple myeloma

与年龄相关的间充质基质细胞衰老与MGUS进展为多发性骨髓瘤有关。

Plakhova, Natalya; Panagopoulos, Vasilios; Cantley, Melissa D; Trainor, Laura J; Hewett, Duncan R; Clark, Kimberley C; Gardiner, Jo; Yong, Angelina; Lee, Cindy; Horvath, Noemi; Croucher, Peter I; Cakouros, Dimitrios; Stewart, Sheila A; Gronthos, Stan; Zannettino, Andrew C W; Mrozik, Krzysztof M; Vandyke, Kate

JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancer.

JNK通路抑制介导ER+乳腺癌对联合内分泌治疗和CDK4/6抑制剂的不敏感性

Alexandrou Sarah, Lee Christine S, Fernandez Kristine J, Wiharja Celine E, Eshraghi Leila, Reeves John, Reed Daniel A, Portman Neil, Phan Zoe, Milioli Heloisa H, Nikolic Iva, Cadell Antonia L, Croucher David R, Simpson Kaylene J, Lim Elgene, Hickey Theresa E, Millar Ewan K A, Alves Carla L, Ditzel Henrik J, Caldon C Elizabeth

Inclusion of JNK-independent drugs within multiagent chemotherapy improves response in relapsed high-risk neuroblastoma

在多药联合化疗中加入JNK非依赖性药物可提高复发性高危神经母细胞瘤的疗效。

Han, Jeremy Z R; Phimmachanh, Monica; Hastings, Jordan F; Leong, King Ho; Ng, Boaz H; Ni, Jenny; Fontaine-Titley, Angela; Cadell, Antonia L; O'Donnell, Yolande Ei; Clearwater, Misaki; Kamili, Alvin; Haber, Michelle; Norris, Murray; Timpson, Paul; Trahair, Toby N; Fletcher, Jamie I; Fey, Dirk; Kolch, Walter; Latham, Sharissa L; Croucher, David R